News Archive
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the…
The GW School of Medicine and Health Sciences has been selected to serve as one of 24 participating sites for the Phase 2 clinical trial to evaluate additional COVID-19 booster shots in adults, including multiple vaccines based on viral variants such as Delta and Omicron.
Scientists created a COVID-19 vaccine in under a year, but there remains no vaccine to stop the AIDS virus. Experts explain how HIV eludes defeat and describe their latest strategies.
A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The trial aims to understand if different vaccine regimens—prototype and variant vaccines alone and in combinations—can broaden immune responses in adults…
Dr. David Diemert, director of The GW Vaccine Research Unit, was interviewed on CTV Your Morning about our current clinical trial of an experimental HIV vaccine.
“The future implications are huge if we could have an effective HIV vaccine that would prevent people from getting the…
George Washington University has collaborated with Moderna to test the safety of the first mRNA HIV vaccines and the immune responses of two participants in the Phase 1 clinical trial. Four institutions, including GW, have enrolled 56 HIV-negative adult participants for the vaccines’ clinical…
The George Washington University is one of four US sites conducting a Phase I clinical trial to test the safety and immune responses of two mRNA vaccine antigens for HIV on 56 healthy adults. The GW Vaccine Research Unit is running one of the study sites and acting as the processing lab and…
IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C…
The Delta variant of the SARS-CoV-2 virus is causing a surge in COVID-19 cases globally, including in the United States, where there has been a sharp increase in reported cases. The Clinical Director of the GW Vaccine Research Unit, Dr. David Diemer, discusses the Delta Variant and the Fourth…
A vaccine for Lassa fever may be on the horizon, thanks to a new clinical trial jointly led by Elissa Malkin, DO, MPH, assistant research professor of medicine at the George Washington University School of Medicine and Health Sciences. With an award from trial sponsor IAVI, Malkin, along with…